Neurobo Pharmaceuticals Probability of Future Stock Price Finishing Over 2.37
| NRBODelisted Stock | USD 2.36 0.01 0.43% |
Neurobo |
Neurobo Pharmaceuticals Target Price Odds to finish over 2.37
The tendency of Neurobo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 2.37 or more in 90 days |
| 2.36 | 90 days | 2.37 | about 89.24 |
Based on a normal probability distribution, the odds of Neurobo Pharmaceuticals to move over $ 2.37 or more in 90 days from now is about 89.24 (This Neurobo Pharmaceuticals probability density function shows the probability of Neurobo Stock to fall within a particular range of prices over 90 days) . Probability of Neurobo Pharmaceuticals price to stay between its current price of $ 2.36 and $ 2.37 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Neurobo Pharmaceuticals has a beta of -0.36. This indicates as returns on the benchmark increase, returns on holding Neurobo Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Neurobo Pharmaceuticals is likely to outperform the market. Additionally Neurobo Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Neurobo Pharmaceuticals Price Density |
| Price |
Predictive Modules for Neurobo Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neurobo Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Neurobo Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neurobo Pharmaceuticals is not an exception. The market had few large corrections towards the Neurobo Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neurobo Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neurobo Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | -0.36 | |
σ | Overall volatility | 0.46 | |
Ir | Information ratio | -0.12 |
Neurobo Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurobo Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurobo Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurobo Pharmaceuticals is now traded under the symbol MTVA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| Neurobo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Cardiometabolic Diseases |
Neurobo Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neurobo Stock often depends not only on the future outlook of the current and potential Neurobo Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurobo Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.1 M | |
| Cash And Short Term Investments | 22.4 M |
Neurobo Pharmaceuticals Technical Analysis
Neurobo Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Neurobo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Neurobo Pharmaceuticals. In general, you should focus on analyzing Neurobo Stock price patterns and their correlations with different microeconomic environments and drivers.
Neurobo Pharmaceuticals Predictive Forecast Models
Neurobo Pharmaceuticals' time-series forecasting models is one of many Neurobo Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Neurobo Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Neurobo Pharmaceuticals
Checking the ongoing alerts about Neurobo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Neurobo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Neurobo Pharmaceuticals is now traded under the symbol MTVA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| Neurobo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Cardiometabolic Diseases |
Check out Neurobo Pharmaceuticals Backtesting, Neurobo Pharmaceuticals Valuation, Neurobo Pharmaceuticals Correlation, Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Volatility, Neurobo Pharmaceuticals History as well as Neurobo Pharmaceuticals Performance. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |